Abstract
Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most common nosocomial infection in the developed world. They cause significant morbidity and mortality, with approximately 150 million cases globally per year. It is estimated that 40-50% of women and 5% of men will develop a UTI in their lifetime, and UTI accounts for more than 1 million hospitalizations and $1.6 billion in medical expenses each year in the USA. Uropathogenic E. coli (UPEC) is the primary cause of UTI. This review presents an overview of the primary virulence factors of UPEC, the major host responses to infection of the urinary tract, the emergence of specific multidrug resistant clones of UPEC, antibiotic treatment options for UPEC-mediated UTI and the current state of vaccine strategies as well as other novel anti-adhesive and prophylactic approaches to prevent UTI. New and emerging themes in UPEC research are also discussed in the context of future outlooks.
Keywords: Antibiotic resistance, uropathogenic Escherichia coli, vaccine, virulence, Urinary Tract Infection, UPEC, UTI, bladder infection (cystitis), acute kidney infection (pyelonephritis), pathogens.
Current Drug Targets
Title:Uropathogenic Escherichia coli Mediated Urinary Tract Infection
Volume: 13 Issue: 11
Author(s): Makrina Totsika, Danilo Gomes Moriel, Adi Idris, Benjamin A. Rogers, Daniel J. Wurpel, Minh-Duy Phan, David L. Paterson and Mark A. Schembri
Affiliation:
Keywords: Antibiotic resistance, uropathogenic Escherichia coli, vaccine, virulence, Urinary Tract Infection, UPEC, UTI, bladder infection (cystitis), acute kidney infection (pyelonephritis), pathogens.
Abstract: Urinary tract infection (UTI) is among the most common infectious diseases of humans and is the most common nosocomial infection in the developed world. They cause significant morbidity and mortality, with approximately 150 million cases globally per year. It is estimated that 40-50% of women and 5% of men will develop a UTI in their lifetime, and UTI accounts for more than 1 million hospitalizations and $1.6 billion in medical expenses each year in the USA. Uropathogenic E. coli (UPEC) is the primary cause of UTI. This review presents an overview of the primary virulence factors of UPEC, the major host responses to infection of the urinary tract, the emergence of specific multidrug resistant clones of UPEC, antibiotic treatment options for UPEC-mediated UTI and the current state of vaccine strategies as well as other novel anti-adhesive and prophylactic approaches to prevent UTI. New and emerging themes in UPEC research are also discussed in the context of future outlooks.
Export Options
About this article
Cite this article as:
Totsika Makrina, Gomes Moriel Danilo, Idris Adi, A. Rogers Benjamin, J. Wurpel Daniel, Phan Minh-Duy, L. Paterson David and A. Schembri Mark, Uropathogenic Escherichia coli Mediated Urinary Tract Infection, Current Drug Targets 2012; 13 (11) . https://dx.doi.org/10.2174/138945012803530206
DOI https://dx.doi.org/10.2174/138945012803530206 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects
Current Medicinal Chemistry Metastasis-Inducing S100A4 Protein: Implication in Non-Malignant Human Pathologies
Current Molecular Medicine Role of Neurotrophins in Spinal Plasticity and Locomotion
Current Pharmaceutical Design Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Antibiotics in Malaria Therapy and their Effect on the Parasite Apicoplast
Current Molecular Medicine Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy
Current Medicinal Chemistry Clearance of Beta-Amyloid in the Brain
Current Medicinal Chemistry Pseudomonas aeruginosa Serious Infections: Mono or Combination Antimicrobial Therapy?
Current Medicinal Chemistry High Throughput Screen Identifies Natural Product Inhibitor of Phenylalanyl-tRNA Synthetase from Pseudomonas aeruginosa and Streptococcus pneumoniae
Current Drug Discovery Technologies Adenosine Monophosphate-activated Protein Kinase (AMPK) Activators For the Prevention, Treatment and Potential Reversal of Pathological Pain
Current Drug Targets New Perspectives of Infections in Cardiovascular Disease
Current Cardiology Reviews Cranial Ultrasound - Optimizing Utility in the NICU
Current Pediatric Reviews Recent Patents Concerning Modulators of Protein Kinase C
Recent Patents on DNA & Gene Sequences Crosstalk between Inflammation and the BBB in Stroke
Current Neuropharmacology The Expanding Universe of γ δ T Lymphocytes: Subsets, Generation and Function
Current Immunology Reviews (Discontinued) Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimers Disease
Current Alzheimer Research Dysfunctions of the Diffusional Membrane Pathways Mediated Hemichannels in Inherited and Acquired Human Diseases
Current Vascular Pharmacology Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Current Status and Future of Antifungal Therapy for Systemic Mycoses
Recent Patents on Anti-Infective Drug Discovery